Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Puma Biotechnology, Inc.NASDAQ: PBYI
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $18.42M rose 5.9% year over year, ahead of the -5.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.
Context
- Selling, general & admin amounted to 31.2% of revenue in FY2025, down 3.6 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $85.55M (+20.1%) for the fiscal year ending Dec 2026, a step up from the -11.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $18.42M+0.2% QoQ
- Last fiscal yearDec 2025
- $71.21M-11.2% YoY
- LTMMar 2026
- $72.24M-5.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 71.21M USD
- Year-over-year change
- -11.2%
- 4-year CAGR
- -11.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.21M | -11.2% |
| FY2024 | 2024-12-31 | 80.16M | -10.2% |
| FY2023 | 2023-12-31 | 89.31M | -0.7% |
| FY2022 | 2022-12-31 | 89.98M | -22.6% |
| FY2021 | 2021-12-31 | 116.29M | — |
Selling, General & Admin vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.3% is the 9th highest of 11, against a peer median of +45.3%.
- Selling, general & admin amounts to 31.8% of revenue for PBYI, versus a peer median of 135.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $158.59M USD | +32.6% | +68.1% | 93.3% | |
| LTM Mar 2026 | $88.42M USD | +83.1% | +48.1% | 178.3% | |
| LTM Sep 2026 | $76.77M USD | +79.2% | +11.4% | — | |
| LTM Mar 2026 | $72.24M USD | -5.3% | -7.5% | 31.8% | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $33.29M USD | +12.6% | +9.8% | — | |
| LTM Mar 2026 | $27.19M USD | +59.1% | +55.2% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥21.46M CNY | +128.2% | -71.8% | — |
| LTM Mar 2026 | CA$18.6M CAD | +58.0% | +35.4% | — | |
| LTM Mar 2026 | $15.86M USD | -38.3% | -16.4% | — | |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
| Peer median (excluding PBYI) | — | +45.3% | +10.6% | 135.8% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 253.16M | 228.03M | 235.64M | 230.47M | 228.37M |
| Cost of Revenue | 63.7M | 55.09M | 62.68M | 64.4M | 58.16M |
| Gross Profit | 189.45M | 172.94M | 172.96M | 166.06M | 170.21M |
| Gross Margin | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% |
| Research & Development | 71.87M | 52.24M | 50.38M | 54.94M | 62.07M |
| Selling, General & Admin | 116.29M | 89.98M | 89.31M | 80.16M | 71.21M |
| Operating Expenses | 188.16M | 149.22M | 140.32M | 135.1M | 132.92M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| EBITDA | (4.69M) | 21.89M | 47.52M | 48.08M | 53.34M |
| EBITDA Margin | -1.9% | 9.6% | 20.2% | 20.9% | 23.4% |
| Operating Income | 1.29M | 23.72M | 32.64M | 30.97M | 37.3M |
| Operating Margin | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% |
| Interest Income | 160K | 813K | 2.61M | 4.72M | 4.08M |
| Interest Expense | 12.81M | 11.59M | 13.33M | 12.45M | 6.62M |
| Other Income / Expenses | (30.09M) | (23.26M) | (9.97M) | (6.87M) | (1.52M) |
| Income Before Tax | (28.8M) | 457K | 22.67M | 24.1M | 35.78M |
| Pre-Tax Margin | -11.4% | 0.2% | 9.6% | 10.5% | 15.7% |
| Income Tax Expense | 324K | 455K | 1.08M | (6.18M) | 4.67M |
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Net Margin | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| EPS (Basic) | (0.72) | 0.02 | 0.46 | 0.62 | 0.62 |
| EPS (Diluted) | (0.72) | 0.02 | 0.45 | 0.62 | 0.61 |
| Weighted Avg Shares | 40.64M | 44.67M | 47.13M | 48.65M | 50.01M |
| Weighted Avg Shares (Diluted) | 40.64M | 44.93M | 47.55M | 49.1M | 50.65M |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.